Daily markets, macro & broker intelligence
H.C. Wainwright has slashed its Neumora Therapeutics price target to $7 following a clinical trial failure, yet controversially maintains its Buy rating — a split signal that demands careful analysis from traders eyeing NRXS.
H.C. Wainwright has reiterated its Buy rating on Caribou Biosciences, reinforcing conviction in the gene-editing biotech at a pivotal moment for both clinical progress and sector sentiment. Here's what the call means for traders and investors across all time horizons.
H.C. Wainwright has reiterated its Buy rating on Caribou Biosciences, keeping the spotlight on one of biotech's most closely watched cell therapy developers. Here's why the call matters and what the charts say right now.